Glucosum Fresenius (Glucose Monohydrate)

Glucosum Fresenius is a prescription‑only solution for injection that contains glucose monohydrate as its active ingredient. It is supplied as an intravenous fluid in a sterile solution form, marketed in the European Union. The product is used as a carbohydrate source for parenteral nutrition, fluid and electrolyte replacement, and to correct low blood‑sugar levels when administered by healthcare professionals.

Glucosum Fresenius is indicated for several clinical situations that require intravenous carbohydrate support and fluid balance. It is commonly employed in hospital settings for patients who cannot receive oral nutrition.

- Parenteral nutrition for patients unable to eat or absorb nutrients orally - Fluid and electrolyte replacement during surgery or critical illness - Treatment of hypoglycemia when rapid glucose delivery is needed - Support during prolonged fasting or pre‑operative preparation - Adjunct to electrolyte solutions in intensive care units

Intravenous administration of Glucosum Fresenius may be associated with a range of observed reactions. Most are mild and self‑limiting, while rare events can be serious.

Common: - Transient hyperglycemia - Local irritation at the infusion site - Mild nausea or vomiting - Headache - Temporary increase in serum osmolality

Serious: - Severe hyperglycemia leading to ketoacidosis - Allergic or anaphylactic reaction - Electrolyte imbalance (e.g., hyponatremia) - Fluid overload with pulmonary edema

Before using Glucosum Fresenius, clinicians should evaluate patient‑specific factors and monitor relevant parameters. Specific considerations include:

- Assess blood glucose levels and adjust infusion rate accordingly - Monitor electrolytes, especially sodium and potassium, during prolonged therapy - Use caution in patients with renal or hepatic impairment - Evaluate risk of fluid overload in heart‑failure or pulmonary disease - Verify compatibility with other intravenous solutions before mixing - Document any prior hypersensitivity to glucose solutions

Glucosum Fresenius can influence or be influenced by other intravenously administered agents. Awareness of potential interactions helps maintain safety.

Avoid: - Co‑administration with high‑dose insulin without glucose monitoring - Simultaneous infusion of incompatible solutions (e.g., calcium-containing fluids) that may precipitate

Use with caution: - Concurrent use of diuretics that affect fluid balance - Beta‑blockers that may mask hypoglycemia symptoms - Corticosteroids that raise blood glucose levels - Total parenteral nutrition regimens containing additional carbohydrate sources